Theradiag SA (ALTHE) - Total Liabilities

Latest as of June 2025: €14.09 Million EUR ≈ $16.47 Million USD

Based on the latest financial reports, Theradiag SA (ALTHE) has total liabilities worth €14.09 Million EUR (≈ $16.47 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Theradiag SA to assess how effectively this company generates cash.

Theradiag SA - Total Liabilities Trend (2001–2024)

This chart illustrates how Theradiag SA's total liabilities have evolved over time, based on quarterly financial data. Check Theradiag SA liquidity resilience to evaluate the company's liquid asset resilience ratio.

Theradiag SA Competitors by Total Liabilities

The table below lists competitors of Theradiag SA ranked by their total liabilities.

Company Country Total Liabilities
Chiu Ting Machinery Co Ltd
TW:1539
Taiwan NT$605.00 Million
Creative Realities Inc
NASDAQ:CREX
USA $39.38 Million
Mabion S.A.
WAR:MAB
Poland zł50.44 Million
Wayi International Digital Entertainment Co
TWO:3086
Taiwan NT$31.83 Million
Symphony Life Bhd
KLSE:1538
Malaysia RM188.59 Million
WiseChip Semiconductor
TWO:5245
Taiwan NT$1.02 Billion
TOP Engineering Co. Ltd
KQ:065130
Korea ₩200.30 Billion

Liability Composition Analysis (2001–2024)

This chart breaks down Theradiag SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Theradiag SA stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.40 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -5.55 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Theradiag SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Theradiag SA (2001–2024)

The table below shows the annual total liabilities of Theradiag SA from 2001 to 2024.

Year Total Liabilities Change
2024-12-31 €11.47 Million
≈ $13.41 Million
-11.86%
2023-12-31 €13.01 Million
≈ $15.21 Million
-2.90%
2022-12-31 €13.40 Million
≈ $15.66 Million
+2.26%
2021-12-31 €13.10 Million
≈ $15.32 Million
-4.95%
2020-12-31 €13.78 Million
≈ $16.12 Million
+30.13%
2019-12-31 €10.59 Million
≈ $12.38 Million
+4.91%
2018-12-31 €10.10 Million
≈ $11.80 Million
-1.96%
2017-12-31 €10.30 Million
≈ $12.04 Million
+12.77%
2016-12-31 €9.13 Million
≈ $10.68 Million
+7.44%
2015-12-31 €8.50 Million
≈ $9.94 Million
+54.25%
2014-12-31 €5.51 Million
≈ $6.44 Million
-18.33%
2013-12-31 €6.75 Million
≈ $7.89 Million
+132.77%
2012-12-31 €2.90 Million
≈ $3.39 Million
+32.55%
2011-12-31 €2.19 Million
≈ $2.56 Million
-16.97%
2010-12-31 €2.63 Million
≈ $3.08 Million
-28.70%
2009-12-31 €3.69 Million
≈ $4.32 Million
+354.93%
2001-12-31 €812.00K
≈ $949.31K
--

About Theradiag SA

PA:ALTHE France Medical Devices
Market Cap
$33.15 Million
€28.36 Million EUR
Market Cap Rank
#23381 Global
#372 in France
Share Price
€0.48
Change (1 day)
-4.95%
52-Week Range
€0.24 - €0.87
All Time High
€8.20
About

Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more